Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oblimersen and Irinotecan in Metastatic Colorectal Cancer
NCT00004870Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Jun 2000
- Primary completion
- Sep 2002
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in colorectal cancer (CRC), sponsored by UT Health San Antonio. Started Jun 2000; status: completed.
02
Drugs
oblimersen
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00004870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004870.